Hwa Jeong Lee Professor

Pharmaceutical Sciences/Division of Pharmacy/Industrial Pharmaceutical Science

이화정 프로필 사진
Dr. Hwa Jeong Lee is a professor of Graduate School of Pharmaceutical Sciences and College of Pharmacy. She is an expert on Biopharmaceutics and Pharmacokinetics. Professor Lee obtained a Ph. D. degree from School of Pharmacy at State University of New York at Buffalo. Her main research areas are pharmacokinetics of new drug candidate/incrementally modified drug and development of efflux transporter inhibitors. She published more than 90 articles in the international journals (SCI).
  • Pharmaceutical Science Building B #102
  • 02-3277-3409
  • Office hours
    • 수 14:00-16:00
Research Record
  • Development of an Ephedrine In-House Matrix Reference Material and Its Application to Doping Analysis ACS OMEGA, 2024, v.9 no.11, 12689-12697
    SCIE Scopus dColl.
  • BEAR: A Novel Virtual Screening Method Based on Large-Scale Bioactivity Data JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, v.63 no.5
    SCIE Scopus dColl.
  • COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein Journal of Pharmaceutical Investigation, 2023, v.53 no.2, 191-212
    SCIE Scopus KCI dColl.
  • Digestive enzyme supplementation in prescription drugs, over-the-counter drugs, and enzyme foods Journal of Pharmaceutical Investigation, 2023, v.53 no.3, 343-355
    SCIE Scopus KCI dColl.
  • Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers Journal of Advanced Research, 2023, v.47, 173-187
    SCIE Scopus dColl.
  • Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia Journal of Critical Care, 2023, v.78, 154402
    SCIE Scopus dColl.
  • Development and evaluation of a digestive formulation using a microbial enzyme for treatment of dyspepsia Journal of Pharmaceutical Investigation, 2022, v.52 no.5, 601-609
    SCIE Scopus KCI dColl.
  • Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.14, 9974-10000
    SCIE Scopus dColl.
  • Discovery of a NADPH oxidase inhibitor, (E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl)amino)benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease European Journal of Medicinal Chemistry, 2022, v.244, 114854
    SCIE Scopus dColl.
  • Drug-like small molecule HSP27 functional inhibitor sensitizes lung cancer cells to gefitinib or cisplatin by inducing altered cross-linked Hsp27 dimers Pharmaceutics, 2021, v.13 no.5, 630
    SCIE Scopus dColl.
  • Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents PHARMACEUTICS, 2021, v.13 no.4, 559
    SCIE Scopus dColl.
  • Optimization, validation, and comparison of a rapid method for the quantification of insulin-like growth factor 1 in serum using liquid chromatography–high-resolution mass spectrometry Drug Testing and Analysis, 2021, v.13 no.2, 451-459
    SCIE Scopus dColl.
  • Quantification of teicoplanin using the hplc-uv method for clinical applications in critically ill patients in Korea Pharmaceutics, 2021, v.13 no.4, 572
    SCIE Scopus dColl.
  • Structural Requirements of 1-(2-Pyridinyl)-5-pyrazolones for Disproportionation of Boronic Acids MOLECULES, 2021, v.26 no.22, 6814
    SCIE Scopus dColl.
  • Design of a Novel Theranostic Nanomedicine (III): Synthesis and Physicochemical Properties of Tumor-Targeting Cisplatin Conjugated to a Hydrophilic Polyphosphazene INTERNATIONAL JOURNAL OF NANOMEDICINE, 2020, v.15, 981-990
    SCIE Scopus dColl.
  • Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, v.35 no.1, 702-712
    SCIE Scopus dColl.
  • Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics PHARMACEUTICS, 2019, v.11 no.1, 23
    SCIE Scopus dColl.
  • Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative PHARMACEUTICS, 2019, v.11 no.9, 482
    SCIE Scopus dColl.
  • Pharmacokinetic alteration of paclitaxel by ferulic acid derivative Pharmaceutics, 2019, v.11 no.11, 593
    SCIE Scopus dColl.
  • Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine BIOMATERIALS, 2018, v.156, 172-193
    SCIE Scopus dColl.
  • Intestinal P-glycoprotein inhibitors, benzoxanthone analogues JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, v.70 no.2, 234-241
    SCIE Scopus dColl.
  • Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies BREAST CANCER RESEARCH AND TREATMENT, 2018, v.170 no.3, 667-675
    SCIE Scopus dColl.
  • Regulation of endogenic metabolites by rosuvastatin in hyperlipidemia patients: An integration of metabolomics and lipidomics CHEMISTRY AND PHYSICS OF LIPIDS, 2018, v.214, 69-83
    SCIE Scopus dColl.
  • Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, v.12
    SCIE Scopus dColl.
  • Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats BIOMOLECULES & THERAPEUTICS, 2017, v.25 no.5, 553-558
    SCIE Scopus KCI dColl.
  • Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor European Journal of Medicinal Chemistry, 2017, v.127, 318-333
    SCIE Scopus dColl.
  • Sensitization of lung cancer cells by altered dimerization of HSP27 Oncotarget, 2017, v.8 no.62, 105372-105382
    SCIE Scopus dColl.
  • 1H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats Journal of Pharmaceutical and Biomedical Analysis, 2016, v.129, 492-501
    SCIE Scopus dColl.
  • A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase SCIENTIFIC REPORTS, 2016, v.6, 22389
    SCIE Scopus dColl.
  • Design of a novel theranostic nanomedicine: Synthesis and physicochemical properties of a biocompatible Polyphosphazene–platinum(II) conjugate International Journal of Nanomedicine, 2016, v.11, 837-851
    Scopus dColl.
  • Development of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis Biomedical Chromatography, 2016, 12 July 2016
    SCIE Scopus dColl.
  • Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I ANTIOXIDANTS & REDOX SIGNALING, 2016, v.24 no.8, 453-469
    SCIE Scopus dColl.
  • Effective killing of cancer cells and regression of tumor growth by K27 targeting sulfiredoxin Free Radical Biology and Medicine, 2016, v.101, 384-392
    SCIE Scopus dColl.
  • Sulfiredoxin inhibitor induces preferential death of cancer cells through reactive oxygen species-mediated mitochondrial damage Free Radical Biology and Medicine, 2016, v.91, 264-274
    SCIE Scopus dColl.
  • Xanthone analogues as potent modulators of intestinal P-glycoprotein EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.93, 237-245
    SCIE Scopus dColl.
  • Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, v.944, 157-165
    SCIE Scopus dColl.
  • Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197) : A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-beta Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.57 no.10, 4213-4238
    SCIE Scopus dColl.
  • Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, v.723, 381-388
    SCIE Scopus dColl.
  • Na+/H+ Exchanger Regulatory Factor 3 Is Critical for Multidrug Resistance Protein 4-Mediated Drug Efflux in the Kidney JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, v.25 no.4, 726-736
    SCIE Scopus dColl.
  • Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile BIOMEDICINE & PHARMACOTHERAPY, 2014, v.68 no.5, 649-655
    SCIE Scopus dColl.
  • Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug JOURNAL OF INORGANIC BIOCHEMISTRY, 2014, v.140, 45-52
    SCIE Scopus dColl.
  • Aripiprazole-montmorillonite: A new organic-inorganic nanohybrid material for biomedical applications Chemistry - A European Journal, 2013, v.19 no.15, 4869-4875
    SCIE Scopus dColl.
  • Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats Xenobiotica, 2013, v.43 no.3, 303-310
    SCIE Scopus dColl.
  • Identification of a New Hexenoic Acid Glycoside and the RSV Principles from Vitis vinifera cv. Muscat of Alexandria Bulletin of the Korean Chemical Society, 2013, v.34 no.6, 1906-1908
    SCIE KCI Scopus dColl.
  • In Vitro and in Vivo Evaluation of Phenylbutenoid Dimers as Inhibitors of P-Glycoprotein JOURNAL OF NATURAL PRODUCTS, 2013, v.76 no.12, 2277-2281
    SCIE Scopus dColl.
  • Synthesis and physicochemical properties of new tripodal amphiphiles bearing fatty acids as a hydrophobic group Bioorganic and Medicinal Chemistry Letters, 2013, v.23 no.6, 1763-1767
    SCIE Scopus dColl.
  • A nanohybrid system for taste masking of sildenafil International Journal of Nanomedicine, 2012, v.7, 1635-1649
    Scopus dColl.
  • Determination of daumone in mouse plasma by HPLC/MS-MS Biomedical Chromatography, 2012, v.26 no.2, 152-155
    SCIE Scopus dColl.
  • Effects of formulation on pharmacokinetics of docetaxel in rats Journal of Pharmaceutical Investigation, 2012, v.42 no.1, 51-55
    KCI Scopus dColl.
  • Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats European Journal of Pharmaceutical Sciences, 2012, v.45 no.3, 296-301
    SCIE Scopus dColl.
  • Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats Biopharmaceutics and Drug Disposition, 2012, v.33 no.6, 292-303
    SCIE Scopus dColl.
  • Nuclear magnetic resonance-based metabolomics for prediction of gastric damage induced by indomethacin in rats Analytica Chimica Acta, 2012, v.722, 87-94
    SCIE Scopus dColl.
  • Preclinical study of a potent P-glycoprotein and cytochrome P450 enzyme inducer rifampicin changing pharmacokinetic parameters of risperidone and its metabolite, 9-hydroxyrisperidone, using a rat model Journal of Pharmaceutical Investigation, 2012, v.42 no.6, 345-351
    KCI Scopus dColl.
  • Quantitative analysis of acetaminophen and its six metabolites in rat plasma using liquid chromatography/tandem mass spectrometry Biomedical Chromatography, 2012, v.26 no.12, 1596-1604
    SCIE Scopus dColl.
  • Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile International Journal of Pharmaceutics, 2012, v.422 no.41276, 374-380
    SCIE Scopus dColl.
  • [학술지논문] Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia JOURNAL OF CRITICAL CARE, 2023, v.78 no.0 , 154402-154402
    SCIE
  • [지적재산권] 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물 Domestic : Patent , Registration , 10-1427291, 2014
Courses
  • 2024-2nd

    • Biopharmaceutics

      • Subject No 22497Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Tue 3~3 (POSCO462)
      • Major Requisite
    • Biopharmaceutics

      • Subject No 22497Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Tue 5~5 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A313)
      • Major Requisite
    • Pharmacokinetics

      • Subject No 38959Class No 01
      • 3Year ( 3Credit , 3Hour)
    • Pharmacokinetics

      • Subject No 39064Class No 01
      • 3Year ( 3Credit , 3Hour)
  • 2024-1st

    • Pharmaceutics

      • Subject No 37134Class No 03
      • 5Year ( 1.5Credit , 1.5Hour) Fri 4~4 (PHM-A104)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A313)
      • Major Requisite
    • Industrial Pharmacy & Administrative Pharmacy Practice

      • Subject No 37153Class No 01
      • 6Year ( 2.5Credit , 160Hour)
      • Major Requisite
    • Introduction to Pharmaceutical Research

      • Subject No 39045Class No 01
      • 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A100-1)
    • Clinical Pharmacokinetics

      • Subject No G16863Class No 01
      • Year ( 3Credit , 3Hour) Tue 2~3 (PHM-)
  • 2022-2nd

    • Biopharmaceutics

      • Subject No 22497Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Mon 5~5 (PHM-A404)
      • Major Requisite
    • Biopharmaceutics

      • Subject No 22497Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Wed 3~3 (PHM-A104)
      • Major Requisite
    • Pharmacokinetics

      • Subject No 37109Class No 01
      • 3Year ( 1.5Credit , 1.5Hour) Wed 2~2 (PHM-A404)
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 04
      • 5Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A313)
      • Major Requisite
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 04
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Advanced Pharmacy Practice and Research Ⅲ

      • Subject No 37156Class No 02
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Honors research

  • 2022-1st

    • Pharmaceutics

      • Subject No 37134Class No 03
      • 5Year ( 1.5Credit , 1.5Hour) Fri 4~4 (PHM-A400)
      • Major Requisite
    • Pharmaceutics

      • Subject No 37134Class No 04
      • 5Year ( 1.5Credit , 1.5Hour) Fri 4~4 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Thu 6~7 (PHM-A313)
      • Major Requisite
    • Industrial Pharmacy & Administrative Pharmacy Practice

      • Subject No 37153Class No 01
      • 6Year ( 2.5Credit , 160Hour)
      • Major Requisite
    • Clinical Pharmacokinetics

      • Subject No G16863Class No 01
      • Year ( 3Credit , 3Hour) Thu 2~3 (-)
  • 2021-2nd

    • Biopharmaceutics

      • Subject No 22497Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Mon 5~5
      • Major Requisite
    • Biopharmaceutics

      • Subject No 22497Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Wed 3~3
      • Major Requisite
    • Pharmacokinetics

      • Subject No 37109Class No 01
      • 3Year ( 1.5Credit , 1.5Hour) Wed 2~2
    • Pharmacokinetics

      • Subject No 37109Class No 02
      • 3Year ( 1.5Credit , 1.5Hour) Wed 2~2
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A313)
      • Major Requisite
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 04
      • 6Year ( 4Credit
      • Major Requisite
    • Advanced Pharmacy Practice and Research Ⅱ

      • Subject No 37155Class No 04
      • 6Year ( 4Credit
      • Major Requisite
    • Advanced Pharmacy Practice and Research Ⅲ

      • Subject No 37156Class No 02
      • 6Year ( 4Credit
      • Major Requisite
  • 2021-1st

    • Pharmaceutics

      • Subject No 37134Class No 03
      • 5Year ( 1.5Credit , 1.5Hour) Mon 2~2
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 01
      • 5Year ( 1.5Credit , 3Hour) Thu 5~6 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 02
      • 5Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A313)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory V

      • Subject No 37137Class No 03
      • 5Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A313)
      • Major Requisite
    • Industrial Pharmacy & Administrative Pharmacy Practice

      • Subject No 37153Class No 01
      • 6Year ( 2.5Credit
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
    • Project Analysis I

      • Subject No G16659Class No 01
      • Year ( 3Credit , 3Hour) Mon 8~9
    • Clinical Pharmacokinetics

      • Subject No G16863Class No 01
      • Year ( 3Credit , 3Hour) Wed 2~3
Academic Background

State University of New York at Buffalo Ph.D.(약제학)

Ewha Womans University 약학석사(약학과)

Ewha Womans University 약학사(제약학과)

Work Experience

Associate Vice President for Office of Research 2014-02-01 ~ 2016-01-31

Vice President for Ewha University-Industry Collaboration Foundation 2014-02-01 ~ 2016-01-31

Director, Business Incubator 2014-02-01 ~ 2015-10-31

Assistant Dean, The College of Pharmacy 2011-08-01 ~ 2013-07-31